Get the Daily Brief
Latest Biotech News
Oncology diagnostics momentum and guidance updates
Guardant Health’s oncology engine kept expanding in Q2, driving total revenue up 44% year over year to $335 million. Oncology revenue grew 38% as oncology test volumes jumped 63%, including a...
FDA adcom decision swings for Replimune’s RP-1 melanoma therapy
FDA advisors backed Replimune’s oncolytic melanoma candidate RP-1, voting 10-3 that the efficacy results are evaluable and clinically meaningful. The panel’s endorsement raises the likelihood the...
Big pharma earnings pressure and strategic recalibration in RNA and diagnostics
Alnylam’s stock slid after it delivered a guidance “one-two punch” by cutting forecasts for its transthyretin amyloidosis franchise amid demand normalization after Amvuttra’s early launch spike....
Tempus scales oncology testing and advances MRD strategy via Personalis
Tempus reported a Q2 revenue lift driven by strong oncology testing momentum and raised full-year 2026 revenue guidance. The company said oncology testing revenue grew 31% year over year,...
Sequencing tools: Illumina raises guidance on clinical application expansion
Illumina raised its 2026 guidance again after Q2 results beat expectations, citing momentum in sequencing-intensive applications among clinical customers. The San Diego-based company forecast 2026...
In vivo CAR-T dealmaking accelerates with J&J and Sail
Johnson & Johnson moved deeper into in vivo CAR-T by paying $785 million upfront to partner with Sail Biomedicines, with an exclusive option to acquire the company for $2.58 billion. The deal...
Cell therapy failure pressures: Capricor’s deramiocel rejected again by FDA panel
An FDA advisory committee voted against approval of Capricor’s deramiocel, a heart-derived cell therapy for Duchenne muscular dystrophy cardiomyopathy, following a contentious review of the Phase...
Strategy and pipeline reshuffling at major pharma: pipeline cuts and R&D cleanup
Biopharma earnings have come with pipeline rethinks, as Takeda, Regeneron, Sanofi, and Bristol Myers Squibb announced program cuts alongside their quarterly updates. The changes signal continued...
AI-enabled cellular discovery: GSK pays for Relation foundation models
Relation Therapeutics secured up to $110 million in a research collaboration with GSK to generate large-scale cellular perturbation data for cellular foundation models. The deal also includes...
Autonomous lab tooling: MGI Tech creates Genoria AI for self-executing experiments
MGI Tech launched Genoria AI, a new AI subsidiary tasked with developing and commercializing lab tools that can plan and execute experiments autonomously. The China-based next-generation...
Melanoma gene therapy faces a critical FDA advisory decision
Replimune’s RP-1 (suvolimogene oderparepvec) took a major step forward as FDA advisers voted 10-3 in favor of the company’s melanoma efficacy case, rejecting arguments that the survival analysis...
Alnylam’s TTR franchise outlook wobbles after earnings guidance cut
Alnylam’s shares fell sharply after the company cut 2026 financial guidance for its transthyretin (TTR) amyloidosis franchise, pointing to demand that “normalized” after an early Amvuttra launch...
Next-gen sequencing tools rebound: Illumina raises 2026 guidance on momentum
Illumina raised its 2026 revenue and earnings guidance after reporting Q2 results that beat consensus and signaled accelerating momentum through the first half of 2026. The sequencing and...
MRD testing provider turns growth into another revenue guidance increase
Adaptive Biotechnologies again increased its 2026 revenue outlook as its minimal residual disease (MRD) business continued to expand. The Seattle-based company now expects 2026 MRD revenue of $268...
Precision cancer cell diagnostics: CareDx lifts 2026 revenue guidance after strong Q2
CareDx increased its full-year 2026 revenue guidance after delivering strong Q2 financial results, including a 52% year-over-year jump in quarterly revenues. The company now expects 2026 revenue...
AI for drug discovery with cellular foundation models: Relation and GSK expand the pact
Relation Therapeutics and GSK announced an expanded research collaboration to generate large-scale cellular perturbation data for cellular foundation models. Under the terms, Relation could...
In vivo CAR-T deal accelerates: J&J partners with Sail Biomedicines
Johnson & Johnson moved deeper into in vivo CAR-T with a collaboration that gives it an option to acquire Sail Biomedicines. J&J will pay $785 million upfront, including a $465 million equity...
Immune reset CAR-T option pricing enters the market conversation
A separate look at the Sail collaboration emphasized the size and structure of the economic terms as J&J expands in vivo CAR-T bets. Alongside the $785 million upfront consideration, J&J receives...
Gene editing infrastructure: OpenABE base editor advances toward next-generation therapy
Researchers at Sungkyunkwan University and the University of Ulsan reported OpenABE, an Open Adenine Base Editor intended to improve the toolkit for adenine base editing used in gene therapy...
Capricor’s Duchenne cell therapy fails FDA adcom amid statistics dispute
Capricor’s deramiocel (allogeneic cell therapy) was rejected by an FDA advisory committee after a meeting centered on conflicting interpretations of the HOPE-3 trial’s statistical analysis plan....